Asian PII Study Launched for Solasia’s PTCL Treatment: Meiji Seika Pharma

Meiji Seika Pharma said on March 28 that its partner Solasia Pharma has launched a multinational PII trial in Asia including Japan for darinaparsin, an investigational treatment for relapsed or refractory peripheral T-cell lymphoma (PTCL). Meiji Seika Pharma concluded a...read more